Since TGF-β signaling is involved in the pathogenesis and progression of various conditions, TGF-β inhibitors are suggested to be promising novel candidates for the treatment of muscular dystrophy, osteoporosis, fibrosis, and cancer. This evidence concerns the gene TGFB1 and muscular dystrophy.